ANKTIVA can grow, but balance sheet bites
- ANKTIVA drove $44.2 million of Q1 2026 net product revenue, up 15% from Q4 2025.
- The stock story depends on turning one bladder cancer drug into a broader cancer platform.
- EU, Saudi Arabia, and Macau approvals give ImmunityBio new launch paths outside the U.S.
- Debt, related-party notes, and RIPA funding keep financial health weak even as sales rise.
- A March 2026 securities suit tied to an FDA OPDP warning letter adds legal noise.
One drug, many cancer shots
ImmunityBio is now a real commercial biotech, not only a research story. Its main product is ANKTIVA, also called N-803. It is an IL-15 superagonist, which means it is designed to wake up immune cells such as natural killer cells and T cells so they can attack cancer better.
The bull case is that ANKTIVA can become a backbone drug. In plain terms, that means doctors could use it with other treatments, such as BCG for bladder cancer or checkpoint inhibitors for lung cancer. Q1 2026 net product revenue was $44.2 million, up 15% from Q4 2025 and up 168% from Q1 2025, so early U.S. demand still looks strong.
The next layer of the story is label expansion. The BCG-naive bladder cancer trial is fully enrolled, with an sBLA planned for 2026. An sBLA is a request to add a new approved use to an existing drug label. The company also refiled an sBLA for BCG-unresponsive papillary-only NMIBC after a 2025 Refusal to File letter.
The bear case is simple. Revenue is still tied to one product, the company remains unprofitable, and the balance sheet is complex. The valuation setup also leaves little room for a slow launch or regulatory setback. If international sales lag, or if the FDA asks for more data, the growth story could lose force fast.
Selling ANKTIVA, funding a platform
Today, ImmunityBio makes money mainly from ANKTIVA product sales. The current core market is U.S. bladder cancer, specifically BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. That is a serious bladder cancer setting where patients have limited choices before more drastic treatment.
Management wants ANKTIVA to fund a larger immunotherapy platform. The company is building around three technologies: ANKTIVA, off-the-shelf natural killer cell therapies including CAR-NK programs, and DNA vaccine vectors. The idea is to combine these tools with each other and with standard cancer treatments.
The model breaks if adoption slows before the pipeline matures. International approvals in the EU, Saudi Arabia, and Macau create new markets, but local reimbursement and partner execution matter. In Europe, Accord Healthcare is the named partner. In the Middle East, Biopharma and Cigalah are key partners.
Financing is another pressure point. The company uses complex funding tools, including RIPA agreements and related-party convertible notes. That can keep trials and launches moving, but it can also limit flexibility and make the stock more sensitive to cash needs.
What ImmunityBio is building
ANKTIVA in bladder cancer
This is the commercial core. It is approved in the U.S. and other jurisdictions for BCG-unresponsive NMIBC carcinoma in situ with or without papillary disease.
ANKTIVA label expansion
The company is pursuing BCG-naive NMIBC, with the pivotal trial fully enrolled and a planned 2026 sBLA. It also refiled an sBLA for BCG-unresponsive papillary-only disease in Q1 2026.
ANKTIVA in lung cancer
Saudi Arabia conditionally approved ANKTIVA in combination with checkpoint inhibitors for metastatic non-small cell lung cancer. This could widen the market, but it still needs launch proof.
Off-the-shelf NK and CAR-NK cells
These programs include PD-L1, CD19, and memory cytokine-enhanced NK cells. They are being studied with ANKTIVA in cancers such as glioblastoma, lymphoma, pancreatic cancer, and breast cancer.
DNA vaccine vectors
The vaccine platform targets areas such as PSA in prostate cancer, HPV in cervical and head and neck cancers, and Lynch syndrome. These are longer-term pipeline bets.
Recombinant BCG, or eBCG
The company is running an expanded access program meant to help address the global shortage of standard BCG. More than 500 patients have been treated in that program.
Revenue is still concentrated
ImmunityBio reports as one operating segment. For Q1 2026, revenue came from ANKTIVA product sales, with no meaningful second commercial revenue stream disclosed.
What could go wrong
Single-product slowdown
High impact · Medium oddsAlmost all current revenue depends on ANKTIVA. If U.S. bladder cancer demand slows, or if doctors wait for more data before broader use, growth could drop quickly. This risk is larger because the rest of the pipeline is not yet a major revenue source.
FDA asks for more data
High impact · Medium oddsThe refiled papillary-only NMIBC sBLA follows a 2025 Refusal to File letter. The key question is whether the FDA accepts and approves it without requiring another randomized controlled trial. A new data request would delay the label expansion and raise costs.
International launch drag
Medium impact · Medium oddsApprovals in the EU, Saudi Arabia, and Macau are useful only if they become sales. Europe needs country-by-country pricing and reimbursement work, and the Middle East launch depends on partners. Slow access could make the global story look better on paper than in revenue.
Balance sheet strain
High impact · High oddsImmunityBio remains unprofitable and carries complex financing. RIPA agreements and related-party convertible notes can reduce room to move. If launch spending or trials require more cash, shareholders may face dilution or tighter financing terms.
Promotion and lawsuit overhang
Medium impact · Medium oddsThe company received an FDA OPDP warning letter tied to promotional activities, including a TV advertisement and podcast interview. A putative securities class action was filed in March 2026 tied to that warning letter. Even if the direct cost is limited, it can distract management and hurt trust.
Pipeline science risk
High impact · Medium oddsThe long-term pitch depends on more than bladder cancer. CAR-NK cells, DNA vaccine vectors, and ANKTIVA combinations still face clinical and regulatory risk. Many cancer programs fail even when early biology looks promising.
In one breath
What does ImmunityBio do?
ImmunityBio develops immunotherapy drugs that try to help the immune system fight cancer. Its lead drug is ANKTIVA, which is already sold for a form of bladder cancer.
Why is ANKTIVA important to IBRX stock?
ANKTIVA is the main source of current revenue and the center of the future growth plan. The stock depends on whether ANKTIVA can expand from one key bladder cancer use into more cancer settings and more countries.
What are the next big ImmunityBio catalysts?
The main events to watch are international launch progress in Europe and Saudi Arabia, FDA action on the refiled papillary-only NMIBC sBLA, and the planned 2026 sBLA for BCG-naive NMIBC.
What is the biggest risk for ImmunityBio?
The biggest risk is concentration. ImmunityBio still depends on one commercial product while carrying a weak and complex financial position.